I see no basis of DM persuing suitors at this point. Slide 42 of the AHA presentation does not indicate such. 

Comments!

Slide 42:
In the near term, we will continue our five-point approach to progressing our corporate commercial value. This approach involves aggressive exploratory development of the following:
•Breakthrough Therapy status filings, both FDA and EMA, over the next 90-120 days
•SGLT2i partnering discussions, one has already been initiated, key patent already filed
•Renal partnering discussions ASAP
•Congestive Heart Failure partnering discussions ASAP, already initiated
•Orphan partnering discussions initially focused on PAH and HIV only at this time. PAH enrollment has already commenced. HIV funding being derived from a yet to be named US-based organization

Koo